Observational Study of HA380 Blood Perfusion Adsorption Combined with Continuous Renal Replacement Therapy in the Treatment of Sepsis

Methods: Forty septic patients who underwent CRRT in our hospital from February 1, 2023 to December 31, 2023 were selected as the study subjects. Based on the sequential admission numbers of the patients, they were randomly divided into a treatment group (TM group) and a control group (Ctrl group), with 20 patients in each group. Both groups of patients received standard treatment and continuous veno-venous hemofiltration (CVVH) until hemodynamic stability was achieved. On this basis, the TM group was accompanied with HA380 BPA therapy, administered at least once within 24 hours of admission, with each perfusion lasting 4 hours, once a day, for a total of 3 times. Statistical analysis was conducted to assess changes in clinical indicators before and after treatment in two patient groups, including rates of adverse events, bleeding events, and the 28-day mortality rate.研究方法：选取2023年2月1日至2023年12月31日于我院接受连续肾脏替代疗法（Continuous Renal Replacement Therapy, CRRT）的脓毒症患者共40例作为研究对象。按照患者的就诊顺序编号，将其随机分为治疗组（TM组）与对照组（Ctrl组），每组各20例。两组患者均接受标准治疗与连续性静脉-静脉血液滤过（Continuous Veno-Venous Hemofiltration, CVVH），直至血流动力学恢复稳定。在此基础上，治疗组额外辅以HA380 BPA治疗：于入院后24小时内至少完成1次治疗，单次灌流时长为4小时，每日治疗1次，总治疗次数为3次。本研究通过统计学分析，评估两组患者治疗前后的临床指标变化情况，涵盖不良事件发生率、出血事件发生率以及28天死亡率。